Literature DB >> 17470590

Transplacental passage of vancomycin in noninfected term pregnant women.

Joann Laiprasert1, Kristin Klein, Bruce A Mueller, Mark D Pearlman.   

Abstract

OBJECTIVE: To evaluate the transplacental passage of vancomycin in term, uninfected pregnant women.
METHODS: A single vancomycin 1-g dose was administered intravenously at four separate time intervals to 13 uncomplicated nonlaboring women undergoing scheduled cesarean delivery. Samples of maternal blood and fetal cord blood were collected at time of delivery and vancomycin concentrations assayed.
RESULTS: Vancomycin concentrations in maternal serum ranged from 2.6 to 19.8 mcg/mL. In cord blood samples, vancomycin concentrations ranged from 2.8 to 9.4 mcg/mL and persisted above the group B streptococci vancomycin breakpoint of 1 mcg/mL. Only 6 of 13 women received the full 1-g vancomycin dose because 53.8% (7 of 13) had some manifestation of red man syndrome during the infusion. No other short term sequelae were identified in any patients or their fetuses. A strong correlation (r(2)=0.93, P<.001) between cord and maternal serum concentrations versus time was noted. Cord vancomycin concentrations approached maternal serum concentrations 4 hours after the infusion ended.
CONCLUSION: Vancomycin crosses the placenta in a predictable manner in concentrations that exceed the usual group B streptococci breakpoint. Adverse events were common, suggesting that longer infusion times and weight adjusted doses should be used.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470590     DOI: 10.1097/01.AOG.0000260388.78339.b6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Adherence to perinatal group B streptococcal prevention guidelines.

Authors:  William P Goins; Thomas R Talbot; William Schaffner; Kathryn M Edwards; Allen S Craig; Stephanie J Schrag; Melissa K Van Dyke; Marie R Griffin
Journal:  Obstet Gynecol       Date:  2010-06       Impact factor: 7.661

2.  Point prevalence study of antibiotic susceptibility of genital group B streptococcus isolated from near-term pregnant women in Calgary, Alberta.

Authors:  Deirdre Church; Julie Carson; Dan Gregson
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

3.  Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model.

Authors:  Medha D Joshi; Gwendolyn M Pais; Jack Chang; Khrystyna Hlukhenka; Sean N Avedissian; Anil Gulati; Walter C Prozialeck; Peter C Lamar; Zhong Zhang; Marc H Scheetz; Brooke Griffin
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 4.  Drugs for the Prevention and Treatment of Sepsis in the Newborn.

Authors:  Sagori Mukhopadhyay; Kelly C Wade; Karen M Puopolo
Journal:  Clin Perinatol       Date:  2019-03-30       Impact factor: 3.430

5.  In Vitro Nephrotoxicity and Permeation of Vancomycin Hydrochloride Loaded Liposomes.

Authors:  Nicole Papp; Jeffin Panicker; John Rubino; Gwendolyn Pais; Alexander Czechowicz; Walter C Prozialeck; Brooke Griffin; Volkmar Weissig; Marc Scheetz; Medha D Joshi
Journal:  Pharmaceutics       Date:  2022-05-28       Impact factor: 6.525

6.  Transplacental transfer of vancomycin and telavancin.

Authors:  Tatiana Nanovskaya; Svetlana Patrikeeva; Ying Zhan; Valentina Fokina; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Am J Obstet Gynecol       Date:  2012-08-04       Impact factor: 8.661

7.  In vitro resistance to macrolides and clindamycin by Group B Streptococcus isolated from pregnant and nonpregnant women.

Authors:  Antonietta Lambiase; Annalisa Agangi; Mariassunta Del Pezzo; Filomena Quaglia; Antonio Testa; Fabio Rossano; Pasquale Martinelli; Maria Rosaria Catania
Journal:  Infect Dis Obstet Gynecol       Date:  2012-05-20

Review 8.  Challenges in reducing group B Streptococcus disease in African settings.

Authors:  Yo Nishihara; Ziyaad Dangor; Neil French; Shabir Madhi; Robert Heyderman
Journal:  Arch Dis Child       Date:  2016-10-18       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.